PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company focused on developing RNA-based therapies for genetic diseases. The company leverages a proprietary drug delivery platform to enhance the effectiveness of RNA therapeutics, targeting conditions where traditional treatments are limited or unavailable.
Why is LSE: BIOG – Biotech Growth Trust stock down today?
Why is LSE:PXS – Provexis stock up 10% today in April 2026?
Why is LSE:TCF – Theracryf Stock Up 15.4% Today on 14 April 2026?
Why is LSE:ONT – Oxford Nanopore Technologies stock up 3% today in April 2026?
Solvonis Therapeutics Plcis a clinical-stage biotechnology company focused on developing innovative therapies targeting addiction, psychiatric, and neurological disorders. The company primarily operates within the central nervous system (CNS) segment, an area with significant unmet medical needs and growing global demand. Its approach combines novel …
Surgical Innovations Group Plcoperates in the medical devices segment, specialising in the development and supply of products used in minimally invasive surgery. The company operates through a diversified model that includes its own branded products, OEM manufacturing, and distribution services. Its strategic focus on …
ValiRx PLC(VAL) is a UK-listed micro-cap biopharmaceutical company focused on developing oncology treatments and companion diagnostics. Trading at approximately 0.320 GBX with a market capitalisation near £2.3 million, the company sits firmly within the biotech penny stock segment.
Trellus Health PLC(TRLS) is a UK-listed micro-cap company operating in the digital healthcare space, with a strong focus on chronic disease management. The stock is currently trading around 0.389 GBX, giving it a market capitalisation of approximately £547,000. Recently, the company has attracted notable …
Verici Dx Plc(VRCI) is a UK-listed healthcare diagnostics company operating within a specialised and high-impact medical niche. Trading near 0.450 GBX with a market capitalisation of approximately £7.19 million, the stock falls into the penny stock category and reflects the risks associated with early-stage …